China’s Essential Drug System Expected To Consolidate Generic Industry, Promote Innovative R&D
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's essential drug system will hasten the consolidation of the generic industry while a measure for drug pricing will encourage innovation, according to a Frost & Sullivan report on the impact of China's healthcare reform, released May 18
You may also be interested in...
China's Changing Drug Market In The Wake Of Essential Drugs List
SHANGHAI - As an important part of China's $850 billion healthcare reform plan, the Essential Drug List system will bring new challenges as well as opportunities for all players in China's drug supply chain
China's Changing Drug Market In The Wake Of Essential Drugs List
SHANGHAI - As an important part of China's $850 billion healthcare reform plan, the Essential Drug List system will bring new challenges as well as opportunities for all players in China's drug supply chain
China To Issue New National Reimbursement List In November; MNC Margin Likely Lower
SHANGHAI - China plans to release a new version of the national reimbursement drug list before the end of November, and multinational companies will likely see lower prices due to a new price negotiation system